scholarly journals Genetically Engineered Phages: a Review of Advances over the Last Decade

2016 ◽  
Vol 80 (3) ◽  
pp. 523-543 ◽  
Author(s):  
Diana P. Pires ◽  
Sara Cleto ◽  
Sanna Sillankorva ◽  
Joana Azeredo ◽  
Timothy K. Lu

SUMMARYSoon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.

2021 ◽  
Vol 4 (3) ◽  
pp. 10728-10744
Author(s):  
Gabriel Monici Vieira ◽  
Débora Oliveira Piva ◽  
Rafaela Lucas Damasceno ◽  
Ricardo de Villa Nova Japiassu ◽  
Anamaria Camargo Macedo ◽  
...  

2020 ◽  
Vol 8 (5) ◽  
pp. 639 ◽  
Author(s):  
Alexis Simons ◽  
Kamel Alhanout ◽  
Raphaël E. Duval

Currently, the emergence and ongoing dissemination of antimicrobial resistance among bacteria are critical health and economic issue, leading to increased rates of morbidity and mortality related to bacterial infections. Research and development for new antimicrobial agents is currently needed to overcome this problem. Among the different approaches studied, bacteriocins seem to be a promising possibility. These molecules are peptides naturally synthesized by ribosomes, produced by both Gram-positive bacteria (GPB) and Gram-negative bacteria (GNB), which will allow these bacteriocin producers to survive in highly competitive polymicrobial environment. Bacteriocins exhibit antimicrobial activity with variable spectrum depending on the peptide, which may target several bacteria. Already used in some areas such as agro-food, bacteriocins may be considered as interesting candidates for further development as antimicrobial agents used in health contexts, particularly considering the issue of antimicrobial resistance. The aim of this review is to present an updated global report on the biology of bacteriocins produced by GPB and GNB, as well as their antibacterial activity against relevant bacterial pathogens, and especially against multidrug-resistant bacteria.


Molecules ◽  
2020 ◽  
Vol 25 (16) ◽  
pp. 3642 ◽  
Author(s):  
Anna Duda-Madej ◽  
Joanna Kozłowska ◽  
Paweł Krzyżek ◽  
Mirosław Anioł ◽  
Alicja Seniuk ◽  
...  

New antimicrobial agents are needed to address infections caused by multidrug-resistant bacteria. Here, we are reporting novel O-alkyl derivatives of naringenin and their oximes, including novel compounds with a naringenin core and O-hexyl chains, showing activity against clinical strains of clarithromycin-resistant Helicobacter pylori, vancomycin-resistant Enterococcus faecalis, methicillin-resistant Staphylococcus aureus, and beta-lactam-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The minimum inhibitory concentrations (MICs), which provide a quantitative measure of antimicrobial activity, were in the low microgram range for the selected compounds. Checkerboard assays for the most active compounds in combination with antibiotics revealed interactions that varied from synergistic to neutral.


Materials ◽  
2021 ◽  
Vol 14 (14) ◽  
pp. 3862
Author(s):  
Latifah Abdullah Alshabanah ◽  
Mohamed Hagar ◽  
Laila A. Al-Mutabagani ◽  
Ghada M. Abozaid ◽  
Salwa M. Abdallah ◽  
...  

Biodegradable nanofibrous hybrid membranes of polyvinyl alcohol (PVA) with ZnO and CuO nanoparticles were manufactured and characterized, and their anti-COVID-19 and anti-multidrug resistant bacteria activities were also evaluated. The morphological structures of the prepared PVA composites nanofibers were observed by scanning electron microscope (SEM), which revealed a homogenous pattern of the developed nanofibers, with an average fibrous diameter of 200–250 nm. Moreover, the results of the SEM showed that the fiber size changed with the type and the concentration of the metal oxide. Moreover, the antiviral and antibacterial potential capabilities of the developed nanofibrous membranes were tested in blocking the viral fusion of SARS-COV-2, as a representative activity for COVID-19 deactivation, as well as for their activity against a variety of bacterial strains, including multi-drug resistant bacteria (MDR). The results revealed that ZnO loaded nanofibers were more potent antiviral agents than their CuO analogues. This antiviral action was attributed to the fact that inorganic metallic compounds have the ability to extract hydrogen bonds with viral proteins, causing viral rupture or morphological changes. On the other hand, the anti-multi-drug resistant activity of the prepared nanofibers was also evaluated using two techniques; the standard test method for determining the antimicrobial activity of immobilized antimicrobial agents under dynamic contact conditions and the standard test method for determining the activity of incorporated antimicrobial agents in polymeric or hydrophobic materials. Both techniques proved the superiority of the ZnO loaded nanofibers over the CuO loaded fibers. The results of the antiviral and antibacterial tests showed the effectiveness of such nanofibrous formulas, not only for medical applications, but also for the production of personal protection equipment, such as gowns and textiles.


2021 ◽  
Vol 8 ◽  
Author(s):  
Dong-Hyun Kim ◽  
Jung-Hyun Kim

The emergence of multidrug-resistant bacteria in companion animals is an increasing concern in view of the concept of One Health. The antimicrobials linezolid (LZD) and tigecycline (TGC) are effective against multidrug-resistant bacteria isolated from humans; however, thus far, no previous study has evaluated the efficacy of these drugs against bacteria isolated from companion animals. This study aimed to evaluate the efficacy of LZD and TGC against bacteria that were isolated from companion dogs and showed resistance to all classes of antimicrobial agents. Clinical samples (auditory channel, eye, skin, and urine) were collected from dogs that visited the Veterinary Medical Teaching Hospital of Konkuk University (Seoul, South Korea) from October 2017 to September 2020. In total, 392 bacterial isolates were obtained, of which 85 were resistant to all classes of antimicrobial agents tested and were, therefore, considered potentially pan-drug resistant (PDR). The susceptibility of isolates to LZD and TGC was determined by the disk diffusion method and interpreted using the Clinical Laboratory Standards Institute guidelines. In total, 95.6% (43/45) and 97.8% (44/45) of gram-positive isolates were susceptible to LZD and TGC, respectively, whereas 82.5% (33/40) of gram-negative isolates were sensitive to TGC. In conclusion, both agents showed favorable efficacy, with the susceptibility rates for all potential PDR bacteria, except Pseudomonas spp., ranging from 72.7 to 100%. Thus, these drugs may serve as excellent antimicrobial options for veterinary medicine in the future.


Viruses ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 295 ◽  
Author(s):  
Sandra-Maria Wienhold ◽  
Jasmin Lienau ◽  
Martin Witzenrath

The emergence of multidrug-resistant bacteria constitutes a great challenge for modern medicine, recognized by leading medical experts and politicians worldwide. Rediscovery and implementation of bacteriophage therapy by Western medicine might be one solution to the problem of increasing antibiotic failure. In some Eastern European countries phage therapy is used for treating infectious diseases. However, while the European Medicines Agency (EMA) advised that the development of bacteriophage-based therapies should be expedited due to its significant potential, EMA emphasized that phages cannot be recommended for approval before efficacy and safety have been proven by appropriately designed preclinical and clinical trials. More evidence-based data is required, particularly in the areas of pharmacokinetics, repeat applications, immunological reactions to the application of phages as well as the interactions and effects on bacterial biofilms and organ-specific environments. In this brief review we summarize advantages and disadvantages of phage therapy and discuss challenges to the establishment of phage therapy as approved treatment for multidrug-resistant bacteria.


Burns ◽  
2010 ◽  
Vol 36 (8) ◽  
pp. 1172-1184 ◽  
Author(s):  
Jessie S. Glasser ◽  
Charles H. Guymon ◽  
Katrin Mende ◽  
Steven E. Wolf ◽  
Duane R. Hospenthal ◽  
...  

2021 ◽  
Author(s):  
Nina Molin Høyland-Kroghsbo ◽  
Bonnie L. Bassler

AbstractBacteriophage (phage) therapy is reemerging as a valuable tool to combat multidrug resistant bacteria. A major hurdle in developing efficacious bacteriophage therapies is that bacteria acquire resistance to phage killing. In this context, it is noteworthy that quorum sensing (QS), the bacterial cell-to-cell communication mechanism that promotes collective undertaking of group behaviors including anti-phage defenses, enhances bacterial survival in the face of phage attack. QS relies on the production, release, accumulation, and detection of signal molecules called autoinducers. In the opportunistic pathogen Pseudomonas aeruginosa, the LasI/R QS system induces the RhlI/R QS system, and these two systems control, in opposing manners, the PQS QS system that relies on the autoinducer called PQS. A ΔlasI mutant is impaired in PQS synthesis, leading to accumulation of the precursor molecule HHQ. HHQ suppresses growth of the P. aeruginosa ΔlasI strain. We uncover a phage infection-induced mechanism that restores expression of the pqsH gene in the P. aeruginosa ΔlasI QS mutant. PqsH converts HHQ into PQS, preventing HHQ-mediated growth inhibition. Thus, phage-infected P. aeruginosa ΔlasI cells exhibit superior growth compared to uninfected cells. Phage infection also restores expression of virulence factors and the CRISPR-cas anti-phage defense system in the P. aeruginosa ΔlasI strain. This study highlights a challenge for phage therapy, namely that phage infection may make particular bacterial strains faster growing, more virulent, and resistant to phage killing.ImportanceThe emergence of multidrug resistant bacteria necessitates development of new antimicrobial therapies. Phage therapy relies on exploiting phages, natural enemies of bacteria, in the fight against pathogenic bacteria. For successful phage therapy development, potent phages that exhibit low propensity for acquisition of bacterial resistance are desired. Here, we show that phage infection restores QS, a cell-to-cell communication mechanism in a P. aeruginosa QS mutant, which increases its virulence and resistance to phage killing. Importantly, clinical isolates of P. aeruginosa frequently harbor mutations in particular QS genes. Thus, phage therapies against such P. aeruginosa strains may inadvertently increase bacterial virulence. Our study underscores the importance of characterizing phage-host interactions in the context of bacterial mutants that are relevant in clinical settings prior to selecting phages for therapy.


Sign in / Sign up

Export Citation Format

Share Document